Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase i dose-escalation study
- Author(s)
- Frederike Lentz, Anne Drescher, Andreas Lindauer, Magdalena Henke, Ralf A. Hilger, Christian Hartinger, Max E. Scheulen, Christian Dittrich, Bernhard Keppler, Ulrich Jaehde
- Abstract
A phase I and pharmacokinetic study was carried out with the new ruthenium complex indazolium trans-[tetrachlorobis(1 H-indazole)ruthenate(lll)] (KP1019, FFC14A). Seven patients with various types of solid tumours refractory to standard therapy were treated with escalating doses of KP1019 (25-600 mg) twice weekly for 3 weeks. No dose-limiting toxicity occurred. Ruthenium plasma concentration-time profiles after the first dose and under multiple-dose conditions were analysed using a compartmental approach. The pharmacokinetic disposition was characterised by a small volume of distribution, low clearance and long half-life. Only a small fraction of ruthenium was excreted renally. The area under the curve values increased proportionally with dose indicating linear pharmacokinetics.
- Organisation(s)
- Department of Inorganic Chemistry
- External organisation(s)
- Rheinische Friedrich-Wilhelms-Universität Bonn, Universität Duisburg-Essen, Sozialmedizinisches Zentrum Süd – Kaiser-Franz-Josef-Spital
- Journal
- ANTI-CANCER DRUGS
- Volume
- 20
- Pages
- 97-103
- No. of pages
- 7
- ISSN
- 0959-4973
- DOI
- https://doi.org/10.1097/CAD.0b013e328322fbc5
- Publication date
- 2009
- Peer reviewed
- Yes
- Austrian Fields of Science 2012
- 104003 Inorganic chemistry, 301305 Medical chemistry
- Portal url
- https://ucrisportal.univie.ac.at/en/publications/b17218c2-3832-4930-9dae-90ff4dac5621